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Abstract
Background The long-term safety of proton pump inhibi-
tors (PPIs) is increasingly questioned. The aim of our study
was to assess the risk of pancreatic cancer among long-
term PPI users in Sweden.
Methods This population-based nationwide Swedish
cohort study including 796,492 adult long-term PPI users
has been used to calculate the standardized incidence rate
ratios (SIRs) and 95% confidence intervals (CI) for pan-
creatic cancer, stratifying by indications of use, age, sex,
and duration of use. The risk among all 20,210 long-term
H2-receptor antagonist users was assessed as comparison.
Results Pancreatic cancer was found in 1733 long-term
PPI users, and 25 H2-receptor antagonist users. For PPI
users, the risk of pancreatic cancer was increased overall
(SIRs = 2.22; 95% CI 2.12–2.32) and in all subgroup
analyses, with the highest risk among PPI-users younger
than 40 years (SIR = 8.90, 95% CI 4.26–16.37), and
among individuals with a history of Helicobacter pylori
(SIR = 2.99, 95% CI 2.54–3.49). After the first year after
enrolment (during which PPI use may be because of early
symptoms of pancreatic cancer), the risk remained
increased over time, with SIR = 1.57 (95% CI 1.38–1.76)
after 5 years. No associations were found for H2-receptor
antagonists (SIR = 1.02, 95% CI 0.66–1.51).
Conclusions This large study showed an increased risk of
pancreatic cancer in long-term users of PPIs in Sweden, in
particular among the youngest users.
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H2RA Histamine-2 receptor antagonist
PPI Proton pump inhibitor
SIR Standardized incidence ratio
Introduction
One of the frequently debated questions in gastro-enterol-
ogy is if the long-term use of proton pump inhibitors (PPI)
is carcinogenic, and if benefits outweigh the risks for all
individuals. Proton pump inhibitors are by far the most
commonly prescribed medications for almost every prob-
lem or discomfort of the upper-gastrointestinal tract,
including gastro-esophageal reflux, (prevention of) peptic
ulcers, gastroduodenitis, dyspepsia or eradication of Heli-
cobacter pylori [1, 2]. PPIs are commercialized in the
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1980s, and since they are extremely potent in suppressing
gastric acid production, close monitoring was initially
required with endoscopies and regular follow-up. Nowa-
days, PPIs are available over-the-counter in many coun-
tries, and easily prescribed yet not easily discontinued,
leading to a steadily increasing amount of long-term users
[1, 3–6]. Noteworthy is that previous studies reported
25–70% of inappropriate use of prescribed PPIs, con-
tributing to polypharmacy and potential drug-drug inter-
actions [1, 7].
Nevertheless, the list of potential side-effects related to
long-term PPI use is increasing, including among others,
chronic kidney disease, osteoporosis and fractures,
Clostridium difficile infections, community acquired
pneumonia, cardiac diseases, and even increased mortality
[8–19]. An increasing number of studies have also inves-
tigated the risk of cancer with most evidence existing for
gastric, colorectal and pancreatic cancer. The two meta-
analyses on gastric cancer (in total including 8 different
studies) concluded that there may be an increased risk in
particular when used over longer periods of time [20, 21].
Yet, the two meta-analyses evaluating colorectal cancer
(including 5 different studies) did not find strong support
for an association [22, 23], although 2 more studies have
been published since showing a significantly increased
risks [24, 25]. For pancreatic cancer, the 12th most com-
mon cancer type, with only 8% 5-year survival [26], we
have identified 6 case–control studies [27–32] and 1 cohort
study [33] of which 3 studies clearly show statistically
increased risks (up to 9-times higher than non-users)
[27, 29, 30]. Yet, methodological heterogeneity and
selection bias may challenge the interpretation of these
findings. Therefore, our aim was to assess the risk of
pancreatic cancer in our previously used Swedish popula-
tion-based cohort study [34–36] to compare the risk of
pancreatic cancer in including individuals receiving PPI
maintenance therapy with the expected risk based on the
total Swedish population.
Methods
This nationwide Swedish population-based cohort study
was designed to compare the risk of pancreatic cancer
among adults (C 18 years) exposed to long-term PPIs
compared to the Swedish background population of the
same sex, age, and calendar year, following an a-priori
established study protocol. The study results are reported
according to the STROBE statement (Strengthening the
Reporting of Observational Studies in Epidemiology) for
cohort studies. This cohort has been described in detail
elsewhere [34, 36], and was approved by the Regional
Ethical Review Board in Stockholm (2014/1291-31/4).
This study has been performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki and later amendments, yet informed consent was
not required because of the registry-based nature of the
data. All individuals, without a history of cancer, were
enrolled between 1st July 2005 (start of the Swedish Pre-
scribed Drug Registry) to 31st December 2012, and fol-
lowed up until the occurrence of any cancer, death or 31st
December 2012 (i.e., end of data collection for Cancer
Registry), whichever occurred first.
Exposure
PPI use was defined by the Anatomic Therapeutic Chem-
ical classification (ATC) system code A02BC, as registered
in the Swedish Prescribed Drug Registry. Long-term PPI
use was defined as C 180 days of exposure to PPI during
the study period before onset of any cancer, approximating
1 month per year or more if close to the maximum follow-
up of 7.5 years. This total cumulative administered PPI
dosage is estimated by adding the defined daily dose per
package (DDDp), which takes the potency of the drug into
account as well as the prescribed quantity with DDD being
the assumed average maintenance dose per day for a drug
used for its main indication in adults according to the
World Health Organization. For comparison reasons, the
risk of pancreatic cancer was also evaluated among all
adults who received C 180 days of exposure to H2-re-
ceptor antagonists, a drug class with similar indications
(ATC code A02BA). All individuals who received both
C 180 days of PPIs and C 180 days of H2RA (N = 25,726
[36] were excluded from all analyses. PPIs are also avail-
able over-the-counter in Sweden since 1999 [6], yet only in
small packages (so at a higher price per dose [37], so we
can assume that long-term users have the large majority of
their PPI doses prescribed.
Outcome
The outcome was cancer of the pancreas, as (compulsory)
registered in the nationwide Cancer Register and defined
by the C25 code of the International Classification of
Diseases, 10th edition (ICD 10). Pancreatic adenocarci-
noma was defined by the histopathological code 096.
Potential confounders/covariates
Age was grouped by age of first PPI prescription and cat-
egorized as 18–40 years, 40–49 years, 50–59 years,
60–69 years, and C 70 years. Sex was grouped as male or
female, and calendar period, as 2005–2006, 2007–2009 and
2010–2012. There was no missing information on these 3
variables.
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Potential confounding by indication was evaluated by
subgroup analyses by indications for gastric acid suppres-
sive therapy. Although these indications are not known as
strong risk factors for pancreatic cancer, a potential pro-
tective effect has been described for long-term aspirin or
other non-steroidal anti-inflammatory drugs (NSAIDs)
[38]. The following 6 subgroups were assessed, as defined
earlier based on the Patient Registry and/or Prescribed
Drug Registry: [29, 30] (1) gastro-esophageal reflux dis-
ease; (2) peptic ulcers; (3) gastroduodenitis; (4) Heli-
cobacter pylori eradication/infection, long-term
(C 180 days during study period) users of (5) aspirin (ATC
codes B01AC06, N02BA) or (6) other NSAIDs (ATC code
M01A) without any of the selected gastrointestinal indi-
cations (including the less prevalent indications dyspepsia,
Barrett esophagus and Zollinger-Ellison syndrome, which
were recorded in B 5% of the present cohort and therefore
not assessed separately). No indication of therapy was
registered for approximately 22% of the cohort [34, 36].
An additional subgroup analyses was conducted for
individuals with diabetes mellitus, a known risk factor for
pancreatic cancer, as defined by the use of any ‘‘drugs used
in diabetes’’ (ATC code A10) before the diagnosis of any
cancer.
Statistical analyses
The risk of developing pancreatic cancer was assessed by
comparing the observed risk among long-term users of
PPIs and the expected risk according to the Swedish
background population of the same age, sex and calendar
period, by means of standardized incidence rate ratios
(SIRs) and 95% confidence intervals (CI) [39]. Expected
incidence rates were calculated based on the Swedish
Cancer Registry and Total Population Registry [40]. Time
of follow-up was calculated from the dispense date of the
first prescription of PPI within the study period, until death,
cancer or end of study period (December 2012), whichever
occurred first. The analyses were stratified by sex, age,
indication, and diabetes mellitus as described above, and
subgroup analyses were conducted for adenocarcinoma
only.
The effect of duration of treatment was assessed by
looking at the risk in relation to the time since the first PPI
prescription, categorized as\ 1.0 year, 1.0–2.9 years,
3.0–4.9 years and more than 5.0 years, as described earlier
[35]. These groups are not mutually exclusive (with one
individual potential contributing person-time to different
groups) as would be the case when using the total estimated
accumulated dosage based on the DDD, with the associated
risk of immortal time-bias in the groups with higher
dosages.
Results
The characteristics of all 796,492 long-term PPI users are
described in Table 1. Approximately 59% of the cohort was
female, and 34% was 70 years or older. Long-term aspirin
and other NSAIDs use were the most common indications,
respectively, in 35% and 30% of the cohort; with relatively
more male aspirin users, and more female NSAIDs users.
Gastro-esophageal reflux, gastroduodenitis, peptic ulcers,
and Helicobacter pylori eradication/infection were recor-
ded for, respectively, 25%, 13%, 10%, and 7% of the
cohort. Diabetes drugs were used prior cancer diagnosis by
3.5% of women and 5.0% of men.
Risk of pancreatic cancer by age and sex
In total, 1733 individuals developed pancreatic cancer, of
which 80.4% were adenocarcinomas. The overall SIR of
pancreatic cancer among long-term PPI users compared to
the Swedish background population, was 2.22 (95% CI
2.12–2.32). The risk estimates were slightly higher for men
(SIR = 2.46, 95% CI 2.30–2.64) than women (SIR = 2.04,
95% CI 2.30–2.64) (Table 2). The highest risk estimate was
found for the youngest age group (SIR = 8.90, 95% CI
4.26–16.37), with the risk estimates decreasing by age
(SIR = 1.81, 95% CI 1.69–1.94 for those C 70 years). The
95% CI of the 4 oldest age-groups did not overlap indi-
cating a statistically significant decrease in risk with
increasing age. Similar results were found when restricting
to adenocarcinomas.
Indications of use
Compared to the Swedish background population, the risk
of pancreatic cancer was higher among PPI long-term users
for all indication groups, with the highest SIRs for those
with a history of Helicobacter pylori infection/eradication
(SIR = 2.99, 95% 2.54–3.49), and the lowest risk for long-
term aspirin users (SIR = 1.55, 95% 1.36–1.77), again with
similar findings for adenocarcinoma only (Table 2). Fig-
ure 1 shows the SIRs for each indication per age group,
with the youngest 3 age-groups merged to obtain sufficient
power. The SIRs were 5–6 times higher for those younger
than 60 with peptic ulcers or gastroduodenitis, and the
lowest SIR (1.40, 95% 1.19–1.64) was found for long-term
aspirin users of 70 years or older.
Risk among individuals with diabetes mellitus
The SIRs for pancreatic cancer in this group was 3.76 (95%
CI 3.19–4.41) and 3.68 (95% CI 3.05–4.41) for pancreatic
adenocarcinoma (Table 2).
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Duration of treatment
During the first year of treatment, the SIRs was 4.35 (95%
CI 4.03–4.68), and even 9.82 (95% CI 8.39–11.42) among
those younger than 60 years (Fig. 2). After this first year,
the risk was still increased, and seemed to increase over
time, from SIR = 1.28 (95% CI 1.16–1.40) between 1 and
3 years after treatment initiation to 1.57 (95% CI
1.38–1.76) after 5 years, with again similar findings when
restricting to adenocarcinomas. Figure 2 shows the results
stratified by age, and this apparent increase over time after
the first year was most consistent among those younger
than 60 years (from SIR = 1.46, 95% CI 1.12–1.88 to
SIR = 2.16, 95% CI 1.64–2.78).
H2-receptor antagonists
Among the 20,210 long-term users of H2-receptor antag-
onists, 25 cases of pancreatic cancer occurred for 113,961
person years of follow-up. The analyses did not find evi-
dence for an association, with SIR = 1.02 (95% CI
0.66–1.51) overall, and SIR = 0.92 (0.49–1.57) among
women and SIR = 1.17 (0.60–2.04).
Discussion
This large population-based study assessing long-term use
of PPIs showed an overall doubled risk of pancreatic
cancer among long-term PPI users compared to Swedish
background population, in particular among the younger
age-groups. Disregarding the first year of use (which may
reflect PPI use because of early symptoms, reverse
causality), the risk increased over time since initiating
treatment in particular among the youngest age-groups, and
the risk increase was shown for all investigated indications
of use. There was no association between the H2-receptor
antagonist use and pancreatic cancer.
The strengths of this study are the population-based
design, the study size with almost 800,000 long-term PPI
users with 4 million years of follow-up; and over 20,000
H2-receptor users as comparison group. The, to our
knowledge, largest studies previously published describing
this association with pancreatic cancer, only included
almost 50,000 PPI users from Korea [33]; and 10,500 H2-
receptor antagonist users in Australia, Canada and the
United States [32]. The maximal duration of follow-up in
the previously published cohort study was 12 years, com-
pared to the 7.5 years in the present study. All PPI use in
the present study is based on prescriptions, eliminating the
Table 1 Description of the all
long-term users of proton pump
inhibitors (defined
as C 180 days accumulated
use) in Sweden during
2005–2012
Total Women Men
Number (%) Number (%) Number (%)
Total 796,492 (100) 465,840 (58.5) 330,652 (41.5)
Age
\ 40 years 88,775 (11.2) 52,780 (11.3) 35,995 (10.9)
40–49 years 103,784 (13.0) 59,440 (12.8) 44,344 (13.4)
50–59 years 155,625 (19.5) 86,756 (18.6) 68,869 (20.8)
60–69 years 177,610 (22.3) 98,012 (21.0) 79,598 (24.1)
C 70 years 270,698 (34.0) 168,852 (36.3) 101,846 (30.8)
Calendar period
2005–2006 437,229 (54.9) 258,700 (55.5) 178,529 (54.0)
2007–2009 227,142 (28.5) 132,730 (28.5) 94,412 (28.6)
2010–2012 132,121 (16.6) 74,410 (16.0) 57,711 (17.5)
Indications of use
Gastro-esophageal reflux 201,744 (25.3) 109,675 (23.5) 92,069 (27.8)
Peptic ulcers 79,546 (10.0) 40,255 (8.6) 39,291 (11.9)
Gastroduodenitis 104,903 (13.2) 59,654 (12.8) 45,249 (13.7)
Helicobacter pylori infection/eradication 58,340 (7.3) 32,082 (6.9) 26,258 (7.9)
Aspirin maintenance therapy 276,941 (34.8) 147,180 (31.6) 129,761 (39.2)
NSAIDs maintenance therapy 241,777 (30.3) 160,632 (34.5) 81,145 (24.5)
Diabetes drugs before cancer diagnosis 33,384 (4.2) 16,531 (3.5) 16,853 (5.0)
Pancreatic cancer 1,733 (0.21) 917 (0.20) 816 (0.25)
Pancreatic adenocarcinoma 1394 (0.18) 742 (0.16) 652 (0.20)
NSAIDs non-steroidal anti-inflammatory drugs
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risk of misclassification because of recall-bias, in particular
because the Swedish Prescribed Drug registry is virtually
complete, although no data are available on in-hospital use
[41]. Yet, some long-term users may not have been iden-
tified if (part of) their PPI use was obtained over-the-
counter instead of by prescription [6]. We also lack
information on PPI use before July 2005, but previous
studies have shown that PPI use overall, and long-term PPI
use are increasing over time, and that discontinuation of
treatment is often over-looked by physicians [1–5].
Therefore, it is difficult to distinguish between prevalent
and incident PPI users, although we assume that many of
those exposed in 2005 were already users prior to enrol-
ment in the present study.
We defined long-term use as an accumulated use of
6 months of more, which was considerably stricter than
other studies looking at PPI use and the risk of gastric
cancer (defined as current use, or minimally 1–2 pre-
scriptions) [20],and pancreatic cancer, all defining PPI use
as C 1 prescription [27–33]. Long-term use ([ 6 months
has only been approved by the Food and Drug Adminis-
tration for pathological hypersecretory conditions such as
the Zollinger–Ellison syndrome; and erosive esophagitis
(based on study data\ 12 months) [42].
Since long-term PPI use is nevertheless common (ap-
proximately 11% of all Swedish adults), using the total
Swedish background population to calculate expected
risks, may have diluted the overall effect [34, 36, 43]. The
total accumulated dosage of PPIs may correlate with an
increasing risk of pancreatic cancer. Yet, as described
earlier, immortal time-bias is a concern [35], and therefore
only data based on time since start of PPI treatment are
calculated and presented. The popularity of PPI use also
makes it unfeasible to find a comparison group with the
same (severity of) symptoms and indications for treatment
not receiving treatment with PPIs or H2-receptor antago-
nists, the most popular yet clearly less common alternative.
Although all results are standardized for age, sex and
Table 2 The risk of pancreatic cancer and pancreatic adenocarcinoma for all long-term proton pump inhibitor users in Sweden (defined
as C 180 days accumulated use), presented as standardized incidence rate ratios (SIRs) and 95% confidence intervals (CI)
Person years Total Adenocarcinoma
N (%) SIRs (95% CI) N (%) SIRs (95% CI)
Total 3,828,553 1733 2.22 (2.12–2.32) 1394 2.26 (2.14–2.38)
Sex
Women 2,275,213 917 2.04 (1.91–2.17) 742 2.10 (1.95–2.26)
Men 1,553,340 816 2.46 (2.30–2.64) 652 2.46 (2.28–2.66)
Age
\ 40 years 333,857 10 8.90 (4.26–16.37) 7 12.30 (4.93–25.34)
40–49 years 475,113 65 5.93 (4.58–7.56) 54 6.62 (4.97–8.63)
50–59 years 729,786 230 3.36 (2.94–3.82) 187 3.29 (2.84–3.80)
60–69 years 954,060 602 2.46 (2.26–2.66) 520 2.47 (2.27–2.70)
C 70 years 1,335,737 826 1.81 (1.69–1.94) 626 1.83 (1.69–1.98)
Indications of use
Gastro-esophageal reflux 979,793 409 2.06 (1.86–2.27) 331 2.01 (1.87–2.33)
Peptic ulcers 359,158 234 2.59 (2.27–2.94) 182 2.56 (2.20–2.96)
Gastroduodenitis 526,036 307 2.75 (2.45–3.08) 245 2.78 (2.44–3.15)
Helicobacter pylori infection/eradication 288,390 160 2.99 (2.54–3.49) 121 2.85 (2.37–3.41)
Long-term aspirin usea 497,202 222 1.55 (1.36–1.77) 173 1.56 (1.33–1.81)
Long-term NSAIDs usea 571,664 210 2.33 (2.03–2.67) 174 2.40 (2.06–2.79)
Diabetes mellitus drugs 164,936 152 3.76 (3.19–4.41) 118 3.68 (3.05–4.41)
Time since start PPIs
First year 979,007 689 4.35 (4.03–4.68) 589 4.62 (4.25–5.01)
1–3 years 2,340,030 414 1.28 (1.16–1.40) 331 1.25 (1.12–1.39)
3–5 years 1,159,914 362 1.40 (1.26–1.55) 286 1.40 (1.25–1.58)
[ 5 years 747,495 268 1.57 (1.38–1.76) 188 1.45 (1.25–1.67)
NSAIDs non-steroidal anti-inflammatory drugs
aNo other gastrointestinal indications recorded
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calendar period, residual confounding may remain.
Smoking, obesity and diabetes, known risk factors for
pancreatic cancer which may also be related to PPI intake,
are unfortunately not collected nationwide for calculations
of SIRs. According to the Public Health Agency of Swe-
den, approximately 50% of the Swedish adults is over-
weight or obese, and 8–11% smoked daily in 2016 [44].
The subgroup analyses on individuals using diabetes
medication also showed increased risks of pancreatic can-
cer, but because of the low proportion of PPI users (4.2%)
diabetes cannot explain the increased overall risk. How-
ever, it is unlikely that residual confounding would fully
explain the increasing risk of pancreatic cancer over time.
Furthermore, the lack of association between H2-antago-
nists and pancreatic cancer diminish the possibility of
indication bias as an explanation for our findings.
Drawing causal relationships in the PPI versus cancer
story is challenging [43], in particular because PPIs are by
far the most commonly prescribed drug for most of its’
indications. In Sweden, long-term use of PPIs is almost 30
times more common than H2-receptor antagonists use
when disregarding those using both drug classes during the
study period [43]. Some of the indications may be unrec-
ognized risk factors for pancreatic cancer, or actually be
early symptoms of pancreatic cancer. This may explain the
very high SIRs during the first year of follow-up, indicating
reverse causality or protopathic bias, in particular among
the youngest age group who may seem unlikely to be at
risk for pancreatic cancer (potentially delaying diagnosis).
Yet, all individuals required an estimated accumulated
duration of exposure of at least 6 months. This should have
eliminated those diagnosed shortly after initiating PPI
treatment, yet an increased risk during that first year was
not unlikely as also seen in our previous papers on gastric
and esophageal cancer (with 7–9 times increased SIRs
compared to the background population) [35]. Since pan-
creatic cancer is a relatively aggressive cancer (with
80–85% presenting with locally advanced or distant
metastatic disease at time of diagnosis [45], it is however
unlikely that early symptoms have been unrecognized
longer than 1 year. In the early stage, most patients are
asymptomatic [46]. Previous studies described abdominal
pain in 25% of individuals up to 6 months prior to diag-
nosis [47], and only few symptoms occurring more than
6 months before diagnosis: back pain, shoulder pain, dys-
phagia, changes in bowel habits, and lethargy [46, 48].
This strongly reduces the risk of reverse causality in
those analyses for the time periods after the first year.
Importantly, the lack of association between H2-antago-
nists (with similar indications as PPI) and pancreatic cancer
further strengthen the hypothesis that long-term PPI use
may be carcinogenic. Finally, the increase in risk over time
after this first year, both overall and for adenocarcinoma
only, also supports our hypothesis that PPI may be an
independent risk factor for pancreatic cancer.
As mentioned above, some epidemiological studies have
been conducted to investigate the association between PPI
use and pancreatic cancer, with 3 out of 7 studies showing
Fig. 1 The risk of pancreatic
cancer among long-term users
of proton pump inhibitors (PPIs)
(defined as C 180 days
accumulated use) compared to
the Swedish background
population, for the most
common indications of use,
stratified per age-group
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strongly increased risks [27, 29, 30], and 4 without any
statistical significant difference [28, 31–33]. Previous epi-
demiological studies also described increased risks of peri-
ampullary cancer, cholangitis and cholecystitis [49–51].
Pre-clinical studies have shown that PPIs can create
hypoacidity and consequently hypergastrinemia which may
result in an overgrowth of pancreatic cells [33, 52]. PPIs
have also been described as the drug-group with the largest
effect on the lower gut microbiome based on population-
based studies [53–56]. Yet, by reducing gastric acidity in
the stomach, the bactericidal effect will also be reduced,
leading to changes in the microbiome of the upper-gas-
trointestinal tract or bacterial overgrowth of potential
harmful bacteria [56]. Regarding the results of the present
study, and our previous studies on gastric and esophageal
cancer showing similar age-dependent effects, a more
thorough investigation of the effect of PPIs on the micro-
biome for different age-groups seems warranted. The
clinical implications of this apparent increased relative risk
of pancreatic cancer may be limited since the absolute, life-
time risk of pancreatic cancer is low (approximately 1.5%
[57]. Yet, since pancreatic cancer is usually diagnosed late,
usually in individuals between 60–80 years [46], it may be
important to be aware of this risk in particular in young
long-term PPI users, because the symptoms are vague, and
may suggest a gastro-esophageal origin. Unfortunately, the
available data did not allow a more in depth analysis of
duration/cumulative dosage among the youngest age-group
because of the low absolute risk.
To conclude, this paper provides evidence for an inde-
pendent association between long-term PPI use and the risk
of pancreatic cancer, based on a large, population-based
nationwide cohort study. Especially the strong increase
among the youngest age-groups warrant attention, since
this may indicate a stronger risk among young individuals
and a higher risk of delayed diagnosis if PPIs are initiated
and continued for early symptoms without more thorough
examination.
Acknowledgements Open access funding provided by Karolinska
Institute.
Author contributions All authors (NB, OSA, and LE) were involved
in the concept and design of the study; NB collected the data and
conducted the analyses, the results were interpreted by all authors
Fig. 2 The risk of pancreatic cancer among long-term users of proton pump inhibitors (PPIs) (defined as C 180 days accumulated use)
compared to the Swedish background population, stratified per age-group and time since initiation of treatment
J Gastroenterol (2020) 55:453–461 459
123
(NB, OSA, LE), NB drafted the manuscript which was critically
revised and approved by OSA and LE. NB obtained the funding for
the project and is the guarantor.
Funding This work was supported by Svenska Lakaresallskapet
(2018, SLS-788751), Bengt Ihres foundation (2018, SLS-788731),
Gastrologisk forskningsfond (2018, SLS-783091). These were not
involved in the study design, collecting or interpreting the data or
drafting the manuscript.
Compliance with ethical standards
Conflicts of interest None declared (financial and personal).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate
if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons licence and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this licence, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing
versus continuation of chronic proton pump inhibitor use in
adults. Cochrane Database Syst Rev. 2017;3:CD011969.
2. Farrell B, Pottie K, Thompson W, et al. Deprescribing proton
pump inhibitors: evidence-based clinical practice guideline. Can
Fam Physician (Medecin de famille canadien). 2017;63:354–64.
3. Halfdanarson OO, Pottegard A, Bjornsson ES, et al. Proton-pump
inhibitors among adults: a nationwide drug-utilization study. Ther
Adv Gastroenterol. 2018;11:1756284818777943.
4. Pottegard A, Broe A, Hallas J, et al. Use of proton-pump inhi-
bitors among adults: a Danish nationwide drug utilization study.
Ther Adv Gastroenterol. 2016;9:671–8.
5. Kim J, Blackett JW, Jodorkovsky D. Strategies for effective
discontinuation of proton pump inhibitors. Curr Gastroenterol
Rep. 2018;20:27.
6. Cohen J. Switching omeprazole in Sweden and the United States.
Am J Ther. 2003;10:370–6.
7. Yucel E, Sancar M, Yucel A, et al. Adverse drug reactions due to
drug–drug interactions with proton pump inhibitors: assessment
of systematic reviews with AMSTAR method. Expert Opin Drug
Saf. 2016;15:223–36.
8. Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and
cause specific mortality associated with proton pump inhibitors
among US veterans: cohort study. BMJ (Clinical research ed).
2019;365:l1580.
9. Xie Y, Bowe B, Li T, et al. Risk of death among users of proton
pump inhibitors: a longitudinal observational cohort study of
United States veterans. BMJ Open. 2017;7:e015735.
10. Sun J, Sun H, Cui M, et al. The use of anti-ulcer agents and the
risk of chronic kidney disease: a meta-analysis. Int Urol Nephrol.
2018;50:1835–43.
11. Qiu T, Zhou J, Zhang C. Acid-suppressive drugs and risk of
kidney disease: a systematic review and meta-analysis. J Gas-
troenterol Hepatol. 2018;33:1566–73.
12. Nochaiwong S, Ruengorn C, Awiphan R, et al. The association
between proton pump inhibitor use and the risk of adverse kidney
outcomes: a systematic review and meta-analysis. Nephrol Dial
Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc.
2018;33:331–42.
13. Poly TN, Islam MM, Yang HC, et al. Proton pump inhibitors and
risk of hip fracture: a meta-analysis of observational studies.
Osteoporos Int J Establ Result Coop Between Eur Found
Osteoporos Natl Osteoporos Found USA. 2019;30:103–14.
14. Islam MM, Poly TN, Walther BA, et al. Adverse outcomes of
long-term use of proton pump inhibitors: a systematic review and
meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1395–405.
15. Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors
therapy and risk of Clostridium difficile infection: systematic
review and meta-analysis. World J Gastroenterol.
2017;23:6500–15.
16. Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of
fractures: an update meta-analysis. Osteoporos Int J Establ Result
Coop Between Eur Found Osteoporos Natl Osteoporos Found
USA. 2016;27:339–47.
17. Lin SM, Yang SH, Liang CC, et al. Proton pump inhibitor use
and the risk of osteoporosis and fracture in stroke patients: a
population-based cohort study. Osteoporos Int J Establ Result
Coop Between Eur Found Osteoporos Natl Osteoporos Found
USA. 2017;29:153–62.
18. Jacob L, Hadji P, Kostev K. The use of proton pump inhibitors is
positively associated with osteoporosis in postmenopausal
women in Germany. Clim J Int Menopause Soc. 2016;19:478–81.
19. Cao F, Chen CX, Wang M, et al. Updated meta-analysis of
controlled observational studies: proton-pump inhibitors and risk
of Clostridium difficile infection. J Hosp Infect. 2018;98:4–13.
20. Wan QY, Wu XT, Li N, et al. Long-term proton pump inhibitors
use and risk of gastric cancer: a meta-analysis of 926 386 par-
ticipants. Gut. 2019;68:762–4.
21. Jiang K, Jiang X, Wen Y, et al. Relationship between long-term
use of proton pump inhibitors and risk of gastric cancer: a sys-
tematic analysis. J Gastroenterol Hepatol. 2019;34:1898–1905.
22. Ahn JS, Park SM, Eom CS, et al. Use of proton pump inhibitor
and risk of colorectal cancer: a meta-analysis of observational
studies. Korean J Fam Med. 2012;33:272–9.
23. Chen S, Song X, Gao X, et al. Proton pump inhibitors and the risk
of colorectal cancer: a meta-analysis. J Clin Gastroenterol.
2011;45:177.
24. Lai SW, Liao KF, Lai HC, et al. Use of proton pump inhibitors
correlates with increased risk of colorectal cancer in Taiwan. Asia
Pac J Clin Oncol. 2013;9:192–3.
25. Hwang IC, Chang J, Park SM. Emerging hazard effects of proton
pump inhibitor on the risk of colorectal cancer in low-risk pop-
ulations: a Korean nationwide prospective cohort study. PLoS
ONE. 2017;12:e0189114.
26. Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of
pancreatic cancer. Cancer J (Sudbury, Mass). 2017;23:333–42.
27. Peng YC, Lin CL, Hsu WY, et al. Proton pump inhibitor use is
associated with risk of pancreatic cancer: a nested case–control
study. Dose Response Publ Int Hormesis Soc.
2018;16:1559325818803283.
28. Hicks B, Friis S, Pottegard A. Use of proton pump inhibitors and
risk of pancreatic cancer. Pharmacoepidemiol Drug Saf.
2018;27:926–30.
29. Kearns MD, Boursi B, Yang YX. Proton pump inhibitors on
pancreatic cancer risk and survival. Cancer Epidemiol.
2017;46:80–4.
30. Lai SW, Sung FC, Lin CL, et al. Use of proton pump inhibitors
correlates with increased risk of pancreatic cancer: a case–control
study in Taiwan. Kuwait Med J. 2014;46:44–8.
460 J Gastroenterol (2020) 55:453–461
123
31. Bradley MC, Murray LJ, Cantwell MM, et al. Proton pump
inhibitors and histamine-2-receptor antagonists and pancreatic
cancer risk: a nested case–control study. Br J Cancer.
2012;106:233–9.
32. Bosetti C, Lucenteforte E, Bracci PM, et al. Ulcer, gastric surgery
and pancreatic cancer risk: an analysis from the International
Pancreatic Cancer Case–Control Consortium (PanC4). Ann
Oncol Off J Eur Soc Med Oncol. 2013;24:2903–10.
33. Hwang IC, Chang J, Park SM. Association between proton pump
inhibitor use and the risk of pancreatic cancer: a Korean
nationwide cohort study. PLoS ONE. 2018;13:e0203918.
34. Brusselaers N, Engstrand L, Lagergren J. Maintenance proton
pump inhibition therapy and risk of oesophageal cancer. Cancer
Epidemiol. 2018;53:172–7.
35. Brusselaers N, Lagergren J, Engstrand L. Duration of use of
proton pump inhibitors and the risk of gastric and oesophageal
cancer. Cancer Epidemiol. 2019;62:101585.
36. Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance ther-
apy with proton pump inhibitors and risk of gastric cancer: a
nationwide population-based cohort study in Sweden. BMJ Open.
2017;7:e017739.
37. FASS (Farmacevtiska specialiteter i Sverige) [database on the
Internet]. 2015. www.fass.se. Accessed 1 July 2019.
38. Brusselaers N, Lagergren J. Maintenance use of non-steroidal
anti-inflammatory drugs and risk of gastrointestinal cancer in a
nationwide population-based cohort study in Sweden. BMJ Open.
2018;8:e021869.
39. Breslow N, Day N. Statistical methods in cancer research: the
design and analysis of cohort studies, chap 3, pp 82–86. Lyon
1987.
40. Statistics Sweden-Statistical Database Population Statistics.
2019. https://www.statistikdatabasen.scb.se/. Accessed 6 Apr
2016.
41. Wettermark B, Hammar N, Fored CM, et al. The new Swedish
Prescribed Drug Register-opportunities for pharmacoepidemio-
logical research and experience from the first 6 months. Phar-
macoepidemiol Drug Saf. 2007;16:726–35.
42. Laine L, Nagar A. Long-term PPI use: balancing potential harms
and documented benefits. Am J Gastroenterol. 2016;111:913–5.
43. Brusselaers N, Engstrand L, Lagergren J. PPI use and oesopha-
geal cancer: what if the results are true? Cancer Epidemiol.
2018;54:139.
44. Public Health Agency of Sweden-Living Conditions and Life-
style. 2019 [cited 2019 30 October 2019]; https://www.
folkhalsomyndigheten.se/the-public-health-agency-of-sweden/liv
ing-conditions-and-lifestyle/. Accessed 22 May 2018.
45. Singhi AD, Koay EJ, Chari ST, et al. Early detection of pan-
creatic cancer: opportunities and challenges. Gastroenterology.
2019;156:2024–40.
46. Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet.
2016;388:73–85.
47. Grahm AL, Andren-Sandberg A. Prospective evaluation of pain
in exocrine pancreatic cancer. Digestion. 1997;58:542–9.
48. Keane MG, Horsfall L, Rait G, et al. A case–control study
comparing the incidence of early symptoms in pancreatic and
biliary tract cancer. BMJ Open. 2014;4:e005720.
49. Chien LN, Huang YJ, Shao YH, et al. Proton pump inhibitors and
risk of periampullary cancers—a nested case–control study. Int J
Cancer. 2016;138:1401–9.
50. Chuang SC, Lin CC, Peng CY, et al. Proton pump inhibitors
increase the risk of cholecystitis: a population-based case-control
study. Gut. 2019;68:1337–9.
51. Schneider J, Weidner W, Hapfelmeier A, et al. The use of proton
pump inhibitors and the spectrum and number of biliary patho-
gens in patients with acute cholangitis. Aliment Pharmacol Ther.
2014;39:1194–203.
52. McDonald JM, Longnecker DS, Bell RH Jr. Effect of hypergas-
trinemia on pancreatic carcinogenesis. Am J Surg.
2002;183:441–4.
53. Le Bastard Q, Al-Ghalith GA, Gregoire M, et al. Systematic
review: human gut dysbiosis induced by non-antibiotic pre-
scription medications. Aliment Pharmacol Ther. 2018;47:332–45.
54. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors
affect the gut microbiome. Gut. 2016;65:740–8.
55. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-
based metagenomics analysis reveals markers for gut microbiome
composition and diversity. Science. 2016;352:565–9.
56. Bruno G, Zaccari P, Rocco G, et al. Proton pump inhibitors and
dysbiosis: current knowledge and aspects to be clarified. World J
Gastroenterol. 2019;25:2706–19.
57. Chhoda A, Lu L, Clerkin BM, et al. Current approaches to pan-
creatic cancer screening. Am J Pathol. 2019;189:22–35.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
J Gastroenterol (2020) 55:453–461 461
123
